Previous 10 | Next 10 |
Gainers: Protagonist Therapeutics (PTGX) +10%. Marriott International (MAR) +7%. Aurora Innovation (AUR) +6%. MannKind Corporation (MNKD) +5%. Arcimoto (FUV) +5%. Losers: Enanta Pharmaceuticals (ENTA) -15%. Cisco Systems (CSCO) -12%. Limelight Networks (LLNW) -5%. Copart (CPRT) -4%....
Protagonist press release (NASDAQ:PTGX): Q1 GAAP EPS of -$0.43 beats by $0.20. License and collaboration revenue of $25.7M (+315.2% Y/Y) beats by $8.65M. For further details see: Protagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65M
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus Presented topline results ...
Ongoing concerns about the health of the global economy sent stocks tumbling on Tuesday, accelerating the downward pressure that has marked most of the past few weeks. With consumer and technology stocks among the worst performers, the Nasdaq led the decline, falling almost 4% and reaching it...
Gainers: Evoke Pharma (EVOK) +151%. Avadel Pharmaceuticals (AVDL) +26%. Arch Resources (ARCH) +21%. Magnachip Semiconductor (MX) +20%. TradeUP Global (TUGCU) +20%. Jiuzi Holdings (JZXN) +19%. Forge Global Holdings (FRGE) +18%. Morphic Holding (MORF) +16%. Flexsteel Industries (FLXS) +15%. Sky...
The shares of Protagonist Therapeutics (NASDAQ:PTGX) have approached a 52-week low even as analysts defend the stock in reaction to the mid-stage data released by the clinical-stage biotech for its ulcerative colitis candidate, PN-943. While the 159-patient trial did not meet the primary endp...
Gainers: Avadel Pharmaceuticals (AVDL) +30%. AgeX Therapeutics (AGE) +9%. Helius Medical Technologies (HSDT) +7%. Quipt Home Medical (QIPT) +7%. Gamida Cell (GMDA) +5%. Losers: Protagonist Therapeutics (PTGX) -47%. Nkarta (NKTX) -14%. ...
Shares of Protagonist Therapeutics (NASDAQ:PTGX) have lost 40.2% to $11.25 in aftermarket trading on Monday, after the company announced data from its phase 2 IDEAL study of its antagonist PN-943 in patients with ulcerative colitis, an inflammatory bowel disease that causes ulcers in the dige...
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PR Newswire PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and e...
Headed into a three-day holiday weekend, stocks lost ground on Thursday, reversing an attempted recovery posted in the previous session. Tech stocks led the retreat, contributing to a 2.1% slide in the Nasdaq. Drug development news provided a significant catalyst during the session. Valneva (...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...